Skip to content
DataLookout
Menu

NCT07607964

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

StatusRecruiting
PhasePhase 1
SponsorAbbVie
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Oct 21, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 15 versions: 13 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 13 → 17 locations
  2. Minor Study sites: 14 to 15
  3. Minor Study sites: 13 to 14
  4. Minor Study sites: 12 to 13
  5. Minor Study sites: 11 to 12
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Eligibility criteria expanded, about 15 words
    • Primary endpoints: details revised at 1 of 7 entries
    • Study sites: 10 to 11
  2. Minor Study sites: 9 to 10v9
  3. Minor Study sites: 10 to 9v8
  4. Minor Study sites: 9 to 10v7
  1. Minor Trial sites expanded: 6 → 9 locationsv6
  2. Minor Study sites: 5 to 6v5
  3. Notable Recruitment opened
    • Study sites: 4 to 5
    v3
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 3 to 4
    • Start date changed from estimate of May 29, 2026 to May 28, 2026
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from Baseline in B Cells in Blood
Timeframe: Up to 365 Days
Maximum Plasma Concentration (Cmax) of ABBV-519.
Timeframe: Up to 85 Days
Time to Cmax (Tmax) of ABBV-519
Timeframe: Up to 85 Days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-519
Timeframe: Up to 85 Days
Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUCt) of ABBV-519
Timeframe: Up to 85 Days
Percentage of Participants with Detection of Anti-Drug Antibodies (ADAs) for ABBV-519
Timeframe: Up to 169 Days
Number of Participants with Adverse Events (AEs)
Timeframe: Up to 425 Days

Arms and interventions

Group 1: Dose AExperimental

Participants will receive a single intravenous (IV) dose of ABBV-519

Group 2: Dose BExperimental

Participants will receive a single intravenous (IV) dose of ABBV-519

Group 3: Dose CExperimental

Participants will receive a single intravenous (IV) dose of ABBV-519

Group 4: Dose DExperimental

Participants will receive a single subcutaneous (SC) dose of ABBV-519

Group 5: Dose EExperimental

Participants will receive a single subcutaneous (SC) dose of ABBV-519

Drugs: ABBV-519

Sites

17 sites in 2 countries

United States 12, Japan 5